Psychedelic Assisted Therapy. Is More Research Needed?

Why Do Regulators Say We Need More Research on Psilocybin Therapy?

If you have been following the conversation around psychedelic therapy, you have probably heard a version of this statement: “The results are promising, but more research is needed.” It appears in policy discussions, media coverage, and clinical guidelines. On the surface, it sounds cautious and responsible. But what does it actually mean?

When it comes to psilocybin-assisted psychotherapy, this phrase reflects a real tension between strong early findings and the realities of scientific rigor, safety, and public health. Understanding this requires looking at both sides. The evidence that is generating excitement, and the limitations that continue to shape regulatory caution.

What the Research Actually Shows

Psilocybin-assisted psychotherapy (PAP) refers to the structured use of psilocybin alongside psychological support, including preparation and integration (Bogenschutz et al., 2017, as cited in Horton et al., 2021; ). It is not simply about the substance itself. The therapeutic context is essential.

Across multiple studies, psilocybin combined with psychotherapy has been shown to reduce symptoms of depression, anxiety, and overall psychological distress (Carhart-Harris et al., 2016; Hendricks et al., 2015, as cited in Carhart-Harris et al., 2016; ). Importantly, these outcomes are not limited to short-term improvements. Some research suggests that benefits can persist for months after treatment.

Randomized controlled trials have demonstrated significant reductions in depression and anxiety scores, with some participants reaching remission (Davis et al., 2021; Raison et al., 2023; von Rotz et al., 2023). In studies involving individuals with end-of-life distress, improvements in mood and quality of life were sustained for up to six months (Griffiths et al., 2016; Ross et al., 2016; ).

Part of what makes these findings compelling is the relatively small number of sessions required. Compared to traditional psychiatric treatments, psilocybin appears to facilitate meaningful psychological change after only one or a few doses (Bogenschutz, 2016).

On a neurobiological level, psilocybin has been shown to decrease activity in the Default Mode Network, a system associated with rigid thinking patterns and rumination often seen in depression (Gattuso et al., 2022; ). This disruption may allow for greater cognitive and emotional flexibility.

At the experiential level, participants often describe a shift from avoidance and shame toward acceptance and self-compassion (Watts et al., 2017; Agin-Liebes et al., 2024; ). Many also report a deepened sense of connection, to themselves, others, and the world (Belser et al., 2017; Agin-Liebes et al., 2024; ). These subjective experiences appear to play a key role in therapeutic outcomes.

So Why Is There Still So Much Caution?

Despite these promising findings, psilocybin research remains in its early stages. Regulators are not dismissing the results. They are asking whether the evidence is strong enough, consistent enough, and generalizable enough to support widespread clinical use.

One major limitation is sample size. Many studies include relatively small numbers of participants, which limits generalizability (Nutt, 2019; ). Larger studies are needed to confirm findings across broader populations.

There are also concerns about participant diversity. Much of the existing research has been conducted with predominantly white, higher socioeconomic groups, which raises questions about applicability across different cultural contexts (Swift et al., 2017; Agin-Liebes et al., 2021; ).

Study design presents additional challenges. Although randomized controlled trials are considered the gold standard, psychedelic research struggles with blinding and placebo conditions. Because the effects of psilocybin are so noticeable, participants and researchers can often infer group assignment, introducing bias (Raison et al., 2023; Griffiths et al., 2016; ).

There is also evidence of positivity bias in the literature. Some studies may emphasize positive outcomes while underreporting negative experiences (Watts et al., 2017; ).

These limitations do not invalidate the findings. They highlight the need for continued, rigorous investigation.

The Reality of Risk and Negative Experiences

Psilocybin is a powerful psychoactive substance. While many participants report meaningful and beneficial experiences, others encounter intense emotional distress during sessions. These experiences can include panic, fear, or overwhelming confrontation with traumatic memories (Belser et al., 2017; Breeksema et al., 2024; ). In clinical settings, these moments are typically supported and integrated into the therapeutic process. Some participants even describe them as necessary for healing.

However, outside of controlled environments, these experiences can pose significant risks. Without proper preparation and integration, individuals may struggle to process what arises. There are also ethical concerns related to altered states of consciousness. Questions remain about informed consent and decision-making capacity during the experience itself (Goodwin & Goodwin, 2017; ). From a regulatory perspective, these risks must be carefully managed before broader implementation.

What “More Research” Actually Means

When regulators call for more research, they are not necessarily questioning whether psilocybin is effective. They are asking for stronger evidence across several domains. This includes larger, more diverse samples, improved study designs, and long-term follow-up data. It also includes a deeper understanding of who benefits most from this treatment and who may be at risk. Many current studies use strict screening criteria, excluding individuals with certain mental health conditions such as psychotic disorders. This may contribute to the positive outcomes observed, but it also limits our understanding of how psilocybin might affect broader populations.

Another critical area is therapist training. Psilocybin-assisted psychotherapy requires specialized skills in preparation, emotional support, and integration. Inadequate training could increase the risk of harm, even in otherwise controlled settings. Research helps establish best practices, ensuring that treatment is delivered safely and ethically.

The Role of Integration in Long-Term Change

One of the most important insights from the literature is that psilocybin itself is not the treatment. The therapeutic process surrounding it is what enables lasting change. PAP typically involves three stages: preparation, dosing, and integration (Horton et al., 2021; ). Integration is particularly important, as it allows individuals to process and apply insights gained during the experience.

Participants often report profound realizations related to their identity, relationships, and past experiences. Without integration, these insights may not translate into meaningful behavioral or emotional change. Harm reduction frameworks emphasize the importance of this process, helping individuals understand both the potential benefits and risks of psilocybin use (Pilecki et al., 2021; ).

The Bigger Picture: Caution and Possibility

The current state of psilocybin research reflects both optimism and uncertainty. On one hand, there is strong evidence suggesting that psilocybin-assisted psychotherapy can produce meaningful and lasting reductions in psychological distress. On the other hand, the research base remains limited in important ways. Regulatory caution is not simply resistance. It is an effort to ensure that, if this treatment becomes widely available, it is implemented safely and responsibly. Psilocybin therapy is moving from the margins of research into mainstream clinical discussion. As it does, the standards for evidence and safety become more rigorous.

So Where Does That Leave Us?

For individuals exploring psychedelic therapy, this conversation is important. The research suggests that psilocybin can be a powerful tool for healing. At the same time, it is not a quick fix. It requires careful preparation, skilled therapeutic support, and meaningful integration. The call for more research should not be interpreted as a lack of evidence. It reflects the need to build on existing findings with greater precision, inclusivity, and safety. Holding both of these realities, the potential for transformation and the need for caution, is essential as the field continues to evolve.

References

Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155–166. https://doi.org/10.1177/0269881119897615

Agin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. (2021). Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy. Journal of Humanistic Psychology. https://doi.org/10.1177/00221678211022949

Agin-Liebes, G., Nielson, E. M., Zingman, M., Kim, K., Haas, A., Owens, L. T., Rogers, U., & Bogenschutz, M. (2024). Reports of self-compassion and affect regulation in psilocybin-assisted therapy. Psychology of Addictive Behaviors, 38(1), 101–113. https://doi.org/10.1037/adb0000935

Belser, A. B., et al. (2017). Patient experiences of psilocybin-assisted psychotherapy. Journal of Humanistic Psychology, 57(4), 354–388. https://doi.org/10.1177/0022167817706884

Bogenschutz, M. P. (2016). It’s time to take psilocybin seriously. The American Journal of Drug and Alcohol Abuse, 43(1), 4–6. https://doi.org/10.1080/00952990.2016.1200060

Davis, A. K., et al. (2021). Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry, 78(5), 481. https://doi.org/10.1001/jamapsychiatry.2020.3285

Gattuso, J. J., et al. (2022). Default mode network modulation by psychedelics. International Journal of Neuropsychopharmacology, 26(3), 155–188. https://doi.org/10.1093/ijnp/pyac074

Goodwin, K. A., & Goodwin, C. J. (2017). Research in psychology: Methods and designs (8th ed.). John Wiley & Sons.

Griffiths, R. R., et al. (2016). Psilocybin produces sustained decreases in depression and anxiety. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513

Nutt, D. (2019). Psychedelic drugs, a new era in psychiatry? Dialogues in Clinical Neuroscience, 21(2), 139–147. https://doi.org/10.31887/dcns.2019.21.2/dnutt

Pilecki, B., et al. (2021). Ethical and legal issues in psychedelic harm reduction. Harm Reduction Journal, 18(1). https://doi.org/10.1186/s12954-021-00489-1

Raison, C. L., et al. (2023). Single-dose psilocybin treatment for major depressive disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530

Ross, S., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512

von Rotz, R., et al. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809

Watts, R., et al. (2017). Patients’ accounts of increased connectedness and acceptance. Journal of Humanistic Psychology, 57(5), 520–564. https://doi.org/10.1177/0022167817709585